好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparison of Clinical Characteristics between Caucasian and Minority Parkinson's Disease Patients
Movement Disorders
P04 - (-)
150
BACKGROUND: PD affects approximately 1% of the population over 60 years with a 2:1 ratio of men to women and a higher proportion of patients with Caucasian background. When considering diagnosis and treatment of patients, it may be important to consider differences in patient populations.
DESIGN/METHODS: Patients with parkinsonism seen at the Movement Disorders Clinic at Boston Medical Center were entered into an established clinical database. Information was collected from the patients, family members, chart review, and the treating physician. Current age, and age of onset and diagnosis were compared between the Caucasian and non-Caucasian groups using t-tests. Male-to-female-ratio, side of onset, family history, disease complications, Hoehn & Yahr Score, current medications, and past medications of the groups were compared using chi-square analysis.
RESULTS: There were a total of 671 distinct patient entries into the database between January 2007 and July 2012, of which 450 were diagnosed with PD. There were a higher proportion of males in the Caucasian subgroup compared to the non-Caucasians subgroup (60% vs. 41.8%, P= 0.002). There was a significantly different pattern of medication use in the groups, with more non-Caucasians on anticholinergics and Caucasians on more levodopa therapy. There were no other significant differences between the groups regarding demographic or clinical characteristics including age at diagnosis, side of onset, disease complications, Hoehn & Yahr score, and past medications.
CONCLUSIONS: In this tertiary care, hospital-based population, there were a higher proportion of males in the Caucasian populations supporting a genetic and/or hormonal influence on PD. There were also differences in medication use between the groups, suggesting treatment and/or response disparities.
Authors/Disclosures

PRESENTER 		No disclosure on file
Marie-Helene Saint-Hilaire, MD, FRCPC, FAAN (Boston University School of Medicine) Dr. Saint-Hilaire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Altec. Dr. Saint-Hilaire has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for advarra. Dr. Saint-Hilaire has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson study group.
Anna D. Hohler, MD, FAAN (Steward SEMC) Dr. Hohler has nothing to disclose.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
Samuel A. Ellias, MD, PhD (Boston University) No disclosure on file
Samuel A. Frank, MD, FAAN (Beth Israel Deaconess Medical Center/Harvard Medical School) Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for uniQure. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Frank has received research support from Huntington's Disease Society of America. The institution of Dr. Frank has received research support from Roche/Genentech. The institution of Dr. Frank has received research support from CHDI Foundation. The institution of Dr. Frank has received research support from Huntington Study Group. The institution of Dr. Frank has received research support from Cerevel.